Long-term benefit of SABR for operable early-stage NSCLC shown in new study

A new study from researchers at The University of Texas MD Anderson Cancer Center showed that stereotactic ablative radiotherapy (SABR) was as effective as surgery at providing long-term benefits to patients with operable early-stage non-small cell lung cancer (NSCLC) and generated minimal side effects. The study is the first of its kind to compare long-term results of SABR against surgical treatment in patients with operable early-stage NSCLC.

Group trial bolsters case for stereotactic radiation therapy for tumors that travel to the lungs

A new study, conducted across 13 medical centers in Australia and New Zealand, strengthens the case for radiation therapy as a treatment for cancer that has begun to spread throughout the body. Findings of the SAFRON II trial (NCT01965223) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Treating spinal metastases with fewer and higher doses of radiation reduces pain more effectively

A new study shows using fewer and higher doses of high-precision radiation therapy is a more effective approach for treating painful spinal tumors than conventional radiation therapy. Findings from the Canadian phase II/III trial (NCT02512965) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.